Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, CSF

3001986
copy
 

Copy Utility


emailprint
Example Reports
Detected
None Detected

Icon

Additional Technical Information
Ordering Recommendation

Aid in diagnosis of contactin associated protein 2 (CASPR2) antibody disorders associated with acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Use to manage antibody-positive (CASPR2) individual following immunotherapy and/or plasmapheresis. Serum is the preferred specimen; see Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, Serum (2009452).

Mnemonic
CASPR2GCSF
Methodology

Semi-Quantitative Indirect Fluorescent Antibody

Performed

Wed

Reported

1-8 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

CSF.

Specimen Preparation

Transfer 0.5 mL CSF to an ARUP Standard Transport Tube. (Min: 0.15 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Contaminated, hemolyzed, or severely lipemic specimens.

Remarks
Stability

Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval

Less than 1:1

Interpretive Data

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes contactin-associated protein-2 (CASPR2) transfected cell lines for the detection and semi-quantification of the CASPR2 IgG antibody.

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note

If CASPR2 antibody IgG is positive, then CASPR2 antibody IgG titer will be added. Additional charges apply.

Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
11/18/2019
X
N/A
CPT Codes

86255; if reflexed, add 86256

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
3001987 CASPR2 Ab IgG Screen by IFA, CSF 90820-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Contactin-Associated Protein-2 Antibody, IgG with Reflex to Titer, CSF